SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-63902"
 

Sökning: id:"swepub:oai:DiVA.org:oru-63902" > Confirmed efficacy ...

Confirmed efficacy of etoposide and dexamethasone in HLH treatment : long-term results of the cooperative HLH-2004 study

Bergsten, Elisabet (författare)
Karolinska Institutet
Horne, AnnaCarin (författare)
Karolinska Institutet
Aricó, Maurizio (författare)
Direzione Generale, Azienda Sanitaria Provinciale, Ragusa, Italy
visa fler...
Astigarraga, Itziar (författare)
Servicio de Pediatria, BioCruces Health Research Institute, Hospital Universitario Cruces, Universidad del Pais Vasco–Euskal Herriko Unibertsitatea (UPV/EHU), Barakaldo, Spain
Egeler, R. Maarten (författare)
Division of Hematology & Oncology, The Hospital for Sick Children, Toronto ON, Canada
Filipovich, Alexandra H. (författare)
Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati OH, USA
Ishii, Eiichi (författare)
Department of Pediatrics, Graduate School of Medicine, Ehime University, Ehime, Japan
Janka, Gritta (författare)
Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany
Ladisch, Stephan (författare)
Center for Cancer and Immunology Research, Children’s Research Institute, Children’s National Medical Center, Washington DC, USA
Lehmberg, Kai (författare)
Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany
McClain, Kenneth L. (författare)
Texas Children’s Cancer Center, Baylor College of Medicine, Houston TX, USA
Minkov, Milen (författare)
University Clinic of Pediatrics, St. Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria
Montgomery, Scott, 1961- (författare)
Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Epidemiology and Public Health, University College London, London, United Kingdom,Clinical Epidemiology and Biostatistics
Nanduri, Vasanta (författare)
Department of Pediatrics, Watford General Hospital, Watford, United Kingdom
Rosso, Diego (författare)
Department of Pediatric Hematology and Oncology, Hospital de Niños Dr Pedro De Elizalde, Buenos Aires, Argentina; Department of Pediatrics, Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
Henter, Jan-Inge (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
American Society of Hematology, 2017
2017
Engelska.
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 130:25, s. 2728-2738
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome comprising familial/genetic HLH (FHL) and secondary HLH. In the HLH-94 study, with an estimated 5-year probability of survival (pSu) of 54% (95% confidence interval, 48%-60%), systemic therapy included etoposide, dexamethasone, and, from week 9, cyclosporine A (CSA). Hematopoietic stem cell transplantation (HSCT) was indicated in patients with familial/genetic, relapsing, or severe/persistent disease. In HLH-2004, CSA was instead administered upfront, aiming to reduce pre-HSCT mortality and morbidity. From 2004 to 2011, 369 children aged <18 years fulfilled HLH-2004 inclusion criteria (5 of 8 diagnostic criteria, affected siblings, and/or molecular diagnosis in FHL-causative genes). At median follow-up of 5.2 years, 230 of 369 patients (62%) were alive (5-year pSu, 61%; 56%-67%). Five-year pSu in children with (n = 168) and without (n = 201) family history/genetically verified FHL was 59% (52%-67%) and 64% (57%-71%), respectively (familial occurrence [n = 47], 58% [45%-75%]). Comparing with historical data (HLH-94), using HLH-94 inclusion criteria, pre-HSCT mortality was nonsignificantly reduced from 27% to 19% (P = .064 adjusted for age and sex). Time from start of therapy to HSCT was shorter compared with HLH-94 (P =020 adjusted for age and sex) and reported neurological alterations at HSCT were 22% in HLH-94 and 17% in HLH-2004 (using HLH-94 inclusion criteria). Five-year pSu post-HSCT overall was 66% (verified FHL, 70% [63%-78%]). Additional analyses provided specific suggestions on potential pre-HSCT treatment improvements. HLH-2004 confirms that a majority of patients may be rescued by the etoposide/dexamethasone combination but intensification with CSA upfront, adding corticosteroids to intrathecal therapy, and reduced time to HSCT did not improve outcome significantly.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Blood (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy